Advancing the Next Generation of iPSC-derived NK Cell and Macrophage Immunotherapies Leading the Legacy of the Most Effective and Affordable Cell Therapies We develop genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage products that are intelligently designed for greater potency and persistence, overcoming the limitations of early cell therapies, for […]
Location: United States, California, San Diego
Employees: 51-200
Total raised: $43M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 21.02.2021 | Logos Capi... | logoscapit... |
| - | Timefolio ... | timefolioc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.04.2021 | - | $43M | - |
Mentions in press and media 10
| Date | Title | Description |
| 02.11.2021 | Shoreline Biosciences Raises $140M | SAN DIEGO, CA, Shoreline Biosciences today announced the completion of a $140 million financing. >> Click here for more funding data on Shoreline Biosciences >> To export Shoreline Biosciences funding data to PDF and Excel, ... |
| 02.11.2021 | Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies | Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Sho... |
| 02.11.2021 | Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies | SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived na... |
| 02.11.2021 | Why American Eagle’s $350 million deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Supply chain logistics. Paid Content How Bayer is innovating to reduce greenhouse gases in farmin... |
| 02.11.2021 | Why American Eagle’s $350 million deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Supply chain logistics. Paid Content Why the marketer experience needs a digital upgrade From Opt... |
| 08.04.2021 | Shoreline Biosciences has raised a $43M round to accelerate the advancement of its proprietary platform to develop new therapies | - |
| 08.04.2021 | Shoreline Biosciences Raises $43M in Financing | Shoreline Biosciences, Inc., a San Diego, CA-based biotechnology company, completed a $43M funding round. The round was led by Boxer Capital, with participation from BVF Partners L.P., Commodore Capital, Cormorant Capital, Janus Henderson I... |
| 07.04.2021 | Shoreline Biosciences Announces $43M Financing To Advance Pipeline Of Allogeneic Natural Killer And Macrophage Cellular Immunotherapies Derived From Pluripotent Stem Cells | SAN DIEGO, April 7, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immu... |
| 07.04.2021 | Shoreline Biosciences Announces $43M Financing To Advance Pipeline Of Allogeneic Natural Killer And Macrophage Cellular Immunotherapies Derived From Pluripotent Stem Cells | |
| - | Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer | Shoreline Biosciences’ work developing “off-the-shelf” cell therapies for cancer has led to strategic partnerships with BeiGene and Gilead Sciences. Now those pharmaceutical companies are joining a $140 million investment in the biotech, wh... |